Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

President and Director

Fred Hutchinson Cancer Research Center

 

Co-Principal Investigator

HIV Trials Network

Seattle, WA

 

Professor of Medicine and Laboratory Medicine

University of Washington

Topics of Professional Interest:

·     HIV vaccine

·     Immunology of herpesvirus

·     Interaction between herpesvirus infection and HIV acquisition

Current Professional Summary:

Dr Corey is President and Director of the Fred Hutchinson Cancer Research Center. He is Co-Principal Investigator of the HIV Vaccine Trials Network and a Professor of Medicine and Laboratory Medicine at the University of Washington.

Committees and Organizations:

·         Chairman, Scientific Advisory Board, Herpes Resource Center, American Social Health Association (1985–2000)

·         Associate Director, Center For AIDS Research (CFAR), University of Washington (1993-2010)

·         Member, National Institute of Allergy and Infectious Diseases (NIAID) AIDS Vaccine Research Working Group (AVRWG) (2003-present)

·         Member, International Research Steering Committee, Fred Hutchinson Cancer Research Center (2006–present)

·         Center for HIV AIDS Vaccine Immunology (CHAVI) Scientific Advisory Board Member (2007–2009)

·         Member, Scientific Advisory Board, South African AIDS Vaccine Initiative (SAAVI) (2007-2009)

·         Elected Selection Committee, Member at Large for Fellows of Medical Sciences Section AAAS (2005-present)

Honors and Awards:
  • Thomas Merigan Lectureship, Stanford University (2007)
  • Jonathan Lax Memorial Lecture, Wistar Institute, HIV Vaccine Development Post STEP (2008)
  • Elected, Institute of Medicine, National Academy of Sciences (2008) 
  • Lifelong AIDS Alliance “Ned Behnke Leadership Award” (2011)
  • Elected, Member, American Academy of Arts and Sciences (2012)
  • Recipient, 2012 Cubist-ICAAC Award, American Society for Microbiology (2012)
Education:

·         BS, with high distinction, University of Michigan, Ann Arbor, 1967

·         MD, University of Michigan Medical School, Ann Arbor, 1971

·         Intern, University of Michigan Medical Center Hospitals, Ann Arbor, 1971-1972

·         Junior Assistant Resident, University of Michigan Medical Center Hospitals, 1972-73

·         Epidemic Intelligence Service Officer, Respiratory and Special Pathogens Branch, Viral Diseases Division, Centers for Disease Control, Atlanta, Georgia, 1973-75

·         Senior Fellow, Division of Infectious Disease, University of Washington, Seattle, Washington, 1975-77

Selected Publications:

1.     Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM, Paavonen J, Ashley Morrow R, Beutner KR, Stratchounsky LS, Keene ON, Watson HA, Tait D, Vargas-Cortez M, for the Valacyclovir HSV Transmission Study Group. Once daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.

 

2.     Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delaney-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L, and HPTN 039 Protocol Team. Effect of acyclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomized, double-blind, placebo-controlled trial. Lancet 2008;371:2109-19. PMC2650104

 

3.     Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, and the Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008 372, 1881-1893. PMC2721012

 

4.     Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009 Aug;15(8):886-92. PMC2723183

 

5.   Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L. Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010 Feb 4;362(5):427-39. PMC2838503

 

6.     Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. PMC2973882

 

7.     Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A. Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons with HSV-2 Infection. JAMA. 2011 Apr 13;305(14):1441-1449. NIHMSID282439

 

8.     Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.  Nat Med. 2011 Mar;17(3):366-71. PMC3053571

 

9.     Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. Ineffectiveness of daily standard and high-dose antiviral therapy in preventing short episodes of genital HSV-2 reactivation: three randomized, open-label cross-over trials. Lancet. 2012 Feb 18;379(9816):641-7.

 

10.  Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN for the Step/ HVTN 504 study team. Extended follow-up of participants in a recombinant adenovirus HIV vaccine trial (Step study) suggests that the increased risk of HIV acquisition among vaccinees wanes over time.  J Infect Dis. 2012 Jul;206(2):258-266.